12月17日，天气寒冷，在杨凌示范区的现代温室大棚内，抗病强、品质优的新品种幼苗正悄然生 长，科研人员携手开展关键技术攻关，种业创新暖流涌动。 "这个棚里展示了400多个番茄杂交试验品种。从9月定植至今，我们持续观察它们的果形与叶部健 康状况，从中筛选优良品种进行培育。"陕西金棚种业有限公司总经理王科说。 一个番茄好品种不仅要口感好，还需具备高产抗逆的特性。"从材料分离、杂交组配，到多轮筛 选，再到品种推广，选育一个番茄新品种往往需要五六年时间。"王科说。 如今，陕西金棚种业有限公司依托杨凌的农科教资源，持续引进研发人才、加大育种投入，已培育 出20个具有影响力的番茄新品种。 在先正达集团中国（杨凌）技术中心育种试验基地的无极调光温室，一盆盆玉米在精准滴灌下茁壮 成长。从嫩芽初绽到穗实饱满，各生长阶段的玉米并存一室。 "我们根据玉米生长所需的红外光谱，合成了红橙光与蓝紫光，并动态调节光的强度，从而使玉米 生长突破季节限制。"先正达集团中国（杨凌）技术中心生产负责人张亚说。 传统育种往往如同拆盲盒，周期长、偶然性大。如今，分子检测等新技术能精准识别具有优良性状 的"潜力股"种子，使育种过程变得更为可控。 种子作 ...

Core Viewpoint - Axbio International Limited is accelerating its IPO process, having submitted its prospectus to the Hong Kong Stock Exchange, with notable backing from prominent investors and a focus on innovative molecular diagnostics and gene sequencing technologies [1][6]. Company Overview - Axbio was founded in 2016 and aims to revolutionize the life sciences tools and diagnostics industry through a next-generation electrochemical detection platform [1]. - The product pipeline includes a microarray chip analyzer, two EL-NGS gene sequencers, and various accompanying test kits [2][3]. Leadership and Background - Founder Tian Hui has a strong academic and professional background, holding degrees from Tsinghua University and Stanford University, and has over 20 years of experience in biotechnology and semiconductor integration [2]. - The company has attracted significant investment from well-known institutions, raising over $110 million across four funding rounds [1][6]. Product Development and Regulatory Milestones - The AxiLona EL-100 microarray chip analyzer received special review status from Jiangsu Province's medical device authority in June 2024 and completed clinical trials by March 2025 [3]. - Axbio is developing the AxiLona AXP-100 gene sequencer, which integrates advanced technologies and aims to offer high precision and low-cost sequencing [5]. Market Growth and Financials - The global molecular diagnostics market grew from $11.1 billion in 2018 to $18.2 billion in 2023, with a CAGR of 10.3%, while China's market expanded from $1.7 billion to $3.1 billion during the same period, with a CAGR of 13.1% [5]. - Axbio reported no revenue in 2023 and projected revenue of $479,000 in 2024, with significant annual losses of $22.9 million and $23.5 million for those years, respectively [10]. Future Prospects - The IPO is crucial for Axbio to enhance its product development, strengthen its technology platform, and expand its commercialization capabilities both domestically and internationally [11]. - Despite current losses, the company's technological advantages and extensive product pipeline position it well for future growth in the molecular diagnostics and gene sequencing markets [11].